EIF4E and colorectal cancer: The results showed that, despite the proven penetrance of ISIS 183750 into the target cells and elicitation of the pharmacodynamic effect of EIF4E inhibition, the combination of ISIS 183750 with irinotecan did not lead to objective results in patients with irinotecan-refractory colorectal cancer, perhaps due to a vast stromal binding of the ASO that may have caused a low cellular uptake.